THE CHARACTERISTICS of multicellular spheroids which include intimate cell-tocell contact and diffusion gradients for oxygen, glucose and other nutrients, makes this a potentially interesting in vitro model for small solid tumours.
Chinese hamster V79 multicellular spheroids were first developed by Sutherland et al. (1971) and subsequently shown to have a number of properties characteristic of radiobiological behaviour in vivo, including the presence of hypoxic cells and the ability to re-oxygenate (Durand & Sutherland, 1976) . More recently the spheroid has been used to investigate cellular responses to chemotherapy (Yuhas et al., 1978a; Sutherland et al., 1979; Twentyman, 1980; Wibe, 1980; West et al., 1980) . It is evident that some of the characteristics of spheroids, such as diffusion gradients (Sutherland et al., 1979; West et al., 1980; Wilson et al., 1981) and the ability to recover from potentially lethal damage (PLD) after drug exposure (Twentyman, 1980) can profoundly influence chemotherapeutic response.
A simplified method of spheroid production using a static culture technique was described by Yuhas et al. (1977) . Subsequently cells from a variety of sources, including some of human origin, were shown to form spheroids and to grow in culture (Yuhas et al., 1978b; Haji-Karim & Carlsson, 1978; Pourreau-Schneider & Malaise, 1981) . Differences in cell proliferation kinetics (Yuhas & Li, 1978) and chemosensitivity response (Yuhas et al., 1979) between multicellular spheroids of different origin have been demonstrated. However, to date there has been no systematic published study which has examined the readiness with w%hich cells from a range of different human tumour types will form spheroids. In this paper we report our studies of spheroid formation using cells derived from 6 different tumour types. Preliminary data on the response of spheroids to a range of cytotoxic drugs is presented and compared with available clinical and in vivo xenograft drug responses.
MATERIALS AND METHODS
Clinical material.-Solid tumour and ascitic fluid was obtained from patients with ovarian cancer undergoing laparotomy or paracentesis. The tumour was transported to the laboratory on ice in Hanks' balanced salt solution. Cells were harvested from ascitic fluid by centrifugation. Pieces of solid tumour were taken for histology; the remainder was used to prepare single-cell suspensions.
Xenograft material.-Human tumour xenografts maintained in serial passage in immunesuppressed mice, prepared as described by Steel et al. (1978) , were excised aseptically from the mouse after cervical dislocation. The excised tumours were washed twice in PBS at 4°C, representative pieces were taken for histology and the remainder used to prepare a single-cell suspension.
Two cell lines derived from metastatic small-cell lung tumours were established in vitro (Ellison et al., 1976, and personal communication) . These cells (designated ME/ MAR and ME/FRE), were used at early passage ( < 20 from explantation) to establish multi-cellular tumour spheroids. Subsequently these cells were shown to form tumours in immune-suppressed mice and to conform with our xenograft nomenclature have been called HX123 (ME/FRE) and HX124 (ME/MAR).
Tumour disaggregation.-The tumours from patient or xenograft were washed, finely chopped and then incubated in filter-sterilized collagenase (Sigma Type II) at a concentration of 2 mg/ml in full medium (Hams F12 (Gibco) + 15% Special Bobby Calf Serum (SBCS) (Gibco) + penicillin 50 u/ml, streptomycin 50 ,Lg/ml and neomycin 10 jg/ml) for 1 h at 37°C. Ten ml of collagenase solution were used per gram of tissue. At the completion of incubation the tumour fragments and cells were centrifuged, washed twice in PBS and then exposed to prewarmed 0-25% trypsin (Bacto) in PBS for 15 min at 37°C. Trypsin activity was inhibited by the addition of SBCS to a final concentration of 15%. Two further washes in PBS with recentrifugation were carried out, followed by the addition of full medium. The resulting suspension was agitated for a further 2-3 min, the large fragments allowed to settle and the supernatant filtered through a 25,um polyester mesh filter. This procedure produces a satisfactory single-cell suspension with cell yields in the range of 1-50x 106 cells/g depending on the tumour type. Cell clumps of 2-4 cells usually constituted < 5% overall cell number.
Spheroid production.-XVe have used the method of Yuhas et al. (1977) with some minor modifications in order to initiate spheroid growth. Routinely 10 ml of 1% agar (Agar Noble, Difco) in full medium was used as a base coat in 9cm bacteriological Petri dishes (Sterilin). Some tumours did not need an agar base coat for spheroid formation, while the melanoma xenografts would not form spheroids unless the agar base coat was 1-5%, as the cells otherwise penetrated the agar. The cells were seeded into dishes at a concentration of 1-3 x 106 cells per dish, gassed with a sterile 5% 02, 5% C02, 90% N2 mixture and incubated at 37°C in sealed polystyrene boxes. Medium was replenished twice weekly.
Treatment with cytotoxic agents.-Spheroids were harvested and sorted into universal containers, washed and re-suspended in 4-5 ml fresh full medium. An appropriate amount of drug in 0-5 ml PBS was then added, and the spheroids incubated for 1 h at 37°C in an atmosphere of 5% 02,5% C02 and 90% N2. At the completion of the drug exposure, treated and control spheroids were washed twice in PBS and re-suspended in full medium. Using an Olympus binocular inverted microscope fitted with micrometer eyepieces at 900 to each other, spheroids of a predetermined size were selected for spheroid growth or cell-survival studies.
Individual spheroids were then pipetted into wells of a 24-well Linbro plate (3-5 ml capacity per well) base coated with 0-5 ml 1% agar in full medium and overlaid with 1 ml of the medium and incubated at 37°C in sealed polystyrene boxes in 5% 02, 5% CO2 and 90% N2. Twelve-24 spheroids were plated for each drug concentration and 24 untreated spheroids were used as controls.
Spheroid growth was asse ssed by measuring the maximum diameter of each spheroid and the diameter at 90°to the maximum and their volumes were then calculated using the formula for ellipsoids. Each spheroid was followed individually throughout the experiment and measured at least twice weekly.
A. C. JONES, I. J. STRATFORD, P. A. WILSON AND M. J. PECKHAIM Spheroids were dissociated into single cells by incubation in prewarmed 0 025% trypsin in PBS for 10 min followed by gentle pipetting. Cell survival was assessed using a twin-layer soft-agar method similar to the one described by Courtenay (1976) . The cells HX70, HX99 and HX34 were plated in medium containing 15% SBCS; however, the small-cell tumour lines (ME/MAR and ME/ FRE) required 15% foetal calf serum instead of SBCS. The agar overlayer was 0 25% agar, the underlayer remained at 0.50 0 made up with Hams F12 and antibiotics as described earlier. Washed August rat red blood cells, treated for 1 h at 44°C, were added to give a final concentration of 1/40 in the agar overlayer. In addition, heavily irradiated cells from dissociated untreated spheroids were employed in all assays to produce a final plated cell number of 104 tumour cells/dish. The plated dishes were incubated at 37°C in 5% 02, 500 C02, 90 N2 for 14-21 days. Cells giving rise to colonies of > 50 cells were scored as survivors.
Drug8. Stock solutions of drugs were made up at a concentration of 1 mg/ml. Adriamycin (Farmitalia) was dissolved in sterile distilled water and used fresh or stored at -20°C for a maximum of 1 month until used. Subsequent dilutions were made in PBS. The remaining drugs were all prepared immediately before use. Melphalan (supplied by the Drug Synthesis and Development Branch, NCI) was dissolved in 2 % HCI in ethanol before dilution with PBS. CCNU (Lundbeck) was dissolved in 20% ethanol in propanediol and diluted in PBS. The Vinca alkaloids (Eli Lilly) and cisplatin (Drug Development and Synthesis Branch, NCI) were dissolved and subsequently diluted in preservative-free PBS. Appropriate control experiments were performed with diluted solvents and these had no detectable effect on spheroid growth.
RESULTS

Spheroid formation
As part of a study examining direct cloning in ovarian cancer, some of the patient material was used in the attempt to initiate spheroid formation. Five patients with adenocarcinoma of the ovary provided untreated solid tumours. Two patients provided ascitic fluid with many cell clumps. In our system the cells obtained from the dissociated tumours all formed aggregates measuring 150-200 /im over a period of 7-10 days. The progress of the aggregates was followed for up to 6 weeks but no further increase in agregate size was observed. Similarly over 4-5 weeks no change was noticed in the appearance of the clumps of cells derived from ascites and no growth occurred. Table I shows the xenografts that were studied to determine whether or not spheroids could be formed from the dissociated tumour cells. Over a range of histologically different tumours, aggregation amongst cells occurred; only 3 tumours failed to produce any significant aggegation. However, of the 19 xenograft tumours that did produce aggregates only 5 (HX34, HX70, HX99, HX123 and HX124) appeared able to form spheroids, which we have defined as aggregates which were both spherical and capable of growth in isolation. There was no clear-cut relationship between spheroid formation, histological type and ability to produce colonies in agar. Fig. 1 . Near-exponential growth was seen for the HX34, HX70, ME/MAR and ME/FRE spheroids over the size range 0-01-0-1 mm3. Volume-doubling times for these Fig. 1 . Generally, for clarity, error bars are omitted from figures; however, statistical analysis was performed on each set of results and statistical differences have been included in figure legends where differences in response were observed.
Response to cytotoxic drugs
The effect of melphalan on the growth of HX70 spheroids is shown in Fig. 2 . In this and subsequent figures, data are normalized to the initial treatment volume. At each of the doses tested melphalan caused growth delay. However, the doses required to delay growth of the lung-adenocarcinoma (HX70) spheroids were considerably higher than those found to be effective against the small-cell carcinoma (ME/MAR, ME/FRE) spheroids. Fig. 3 shows that doses as low as 05 ,ug/ml caused growth delay in both small-cell carcinoma lines. Furthermore, treatment of 234,um-diameter ME/MAR spheroids with 0-1 ,ug/ml melphalan was sufficient to cause progressive break-up of the spheroid. This was due to the lethal effect of 1I0 p,g/ml melphalan onME/MARspheroids of this size. Melphalan at a concentration of 10 ,ug/ml was found to be effective in causing growth delay (as shown in Fig. 4 3-0 ug/ml was significant (P <0.001) and the difference between 3 0 ug/ml and 10 0 ,Ag/ml was also highly significant (P < 0 001) (using Student's t-test).
Within the range of achievable peak plasma levels in man (06 ,ug/ml, Alberts & Chen, 1980) (HX34) and breast (HX99)-derived spheroids after exposure to melphalan at various concentrations for 1 h. For HX99 a statistical difference was observed at Day 13 between control and 1-0 ,ug/ml (P < 0-01) but not between 1-0 ,ug/ml and 2-0 ug/ml. For HX34 a statistical difference between control and 1-0 jug/ml was also observed (P < 0-01).
higher concentrations of drug than were used in these experiments with the smallcell tumours ME/FRE and ME/MAR (West, Stratford & Jones, in preparation). The melanoma spheroids (HX34) appeared unresponsive at clinically achiev- and 1-0 t*g/ml and between 1-0 Zg/ml and 3-0 ,ug/ml (P <0-001) for HX34.
Similarly a significant difference between control and 0-5 jug/ml at Day 13 for HX99 was also observed (P < 0-02). However, no significant difference was found between 0-5 jug/ml anid 1-0 ug/ml. concentration of vindesine induced growth delay in the other small-cell-carcinomaderived spheroids ME/MAR. Vincristine was observed to cause dose-dependent growth delay in the breast-tumour spheroids (HX99 xenografts that were examined, only a limited number went on to exhibit growth of spheroids from aggregates. As a capacity for in vitro colony formation has been demonstrated for most of the xenografts (Table I) , the infrequency of spheroid formation is interpreted as being at least partly due to sub-optimal growth conditions rather than an inherent inability of the tumours to grow in vitro. Factors that will increase the ability of tumour cells in vitro to form spheroids are under investigation. The enhanced plating efficiency of cells derived from spheroids, compared with those obtained from xenografts (Table II Experiments are in progress using cellsorting techniques to examine the nature and origin of the phenomenon of increased plating efficiency.
The growth curves obtained for the 5 tumour lines (Fig. 1) differ from each other, but are broadly similar to those that have been reported for other human lines grown from spheroids (Byfield et al., 1980; Haji-Karim & Carlsson, 1978; PourreauSchneider & Malaise, 1981) . The growth fraction of multicellular spheroids has been shown to be a major determinant of growth rate (Yuhas & Li, 1978) . In our study a correlation exists between growth rate and plating efficiency ( Fig. 1 and Table II ). The low growth rate observed with the breast-carcinoma spheroids (HX99) has previously been reported for other human-breast-carcinoma spheroids (Yuhas & Li, 1978) .
Most reported studies concerning spheroids have used cell survival as the principal end-point. Growth delay has received less attention but nevertheless has shown a dose-dependent response to radiation and drugs (Durand, 1976; Pourreau-Schneider & Malaise, 1981; Yuhas et al., 1978a; Twentyman, 1980 Alberts & Chen, 1980) . For melphalan, pharmacokinetic data obtained after i.v. high-dose administration were also used (McElwain et al., 1979) . It has been possible to compare the spheroid response with that observed in the patient in only a proportion of cases, since not all patients received chemotherapy (Table III) . In addition, comparison has been further restricted by the frequent use of drug combinations to treat patients and the consequent difficulty of ascribing the clinical response to a particular drug. As a result the spheroid response was also compared with the xenograft tumour response, particularly as xenografts are being recognized increasingly as exhibiting a response that reflects that seen in the patient (Nowak et al., 1978; Shorthouse et al., 1980) . The responses that have been observed in our tumour spheroids and the patient and xenograft responses are summarized in Table III . The clinically resistant tumours (HX34 and HX70) were drugresistant when treated as spheroids, while the small-cell tumours (ME/FRE and ME/MAR) showed a mixed response in vitro. Concordance between the xenograft response using growth delay as the end-point and the spheroid response was also seen.
Our data would suggest that spheroid formation from human tumour material does not occur with the same frequency and readiness as spheroid formation from established in vitro cell lines (Yuhas et al., 1977) . Despite this, we feel that spheroids derived from a range of human tumours do merit further attention as an in vitro tumour model since they appear to show differences in drug responsiveness in keeping with their tumour of origin.
